Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta‐analysis
Authors' conclusion
Metformin might correlate with a lower dementia incidence in people with T2DM. However, it is crucial to interpret these results with caution considering the high heterogeneity.
Study context
- Population
- People with T2DM; cohort studies comparing metformin with other antidiabetic drugs or no therapy; databases searched until 9 April 2024
- Participants
- 3,463,100 people20 cohort studies
- Comparison
- Metformin vs non-use, SU or TZD
- Outcome
- Incidence of all-cause dementia
Methodological detailsrandom effects model
- Random effects model
Pooled result
As reported in the abstract
All-cause dementia
Hazard ratio (95% CI)P value
Metforminvs Non-usern = 17; I2 = 98.9%
0.76(0.65–0.91)
P = 0.002Metforminvs Sulfonylureasn = 5; I2 = 9.7%
0.88(0.85–0.90)
P < 0.001Metforminvs Thiazolidinedionen = 2; I2 = 92.7%
0.53(0.08–3.41)
P = 0.503Further pooled results
All-cause dementia, non-specified T2DM
| HR (95% CI) | ||
|---|---|---|
| Metforminn = 19 | 0.75 (0.64–0.89) | |
| 0.512Hazard ratio (log scale) |
All-cause dementia, newly diagnosed T2DM
| HR (95% CI) | ||
|---|---|---|
| Metforminn = 5 | 1.01 (0.81–1.27) | |
| 0.512Hazard ratio (log scale) |
Original publication
Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →